Clinical Trial of Favipiravir Treatment of Patients With COVID-19
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
To verify that the efficacy of favipiravir exceeds that of the actual supportive care
(symptomatic therapy) in SARS-CoV-2 infected patients (COVID-19 patients) with mild
pneumonia, using the time required to improve clinical symptoms as the primary endpoint.
Phase:
Phase 3
Details
Lead Sponsor:
University of Pecs
Collaborators:
HECRIN Consortium Hungarian Ministry of Innovation and Technology